Meeting
2023 ASCO Annual Meeting
Cost-effectiveness analyses of population-based multi-gene testing for the prevention of breast and ovarian cancer in the United States.
Authors
Fangjian Guo
University of Texas Medical Branch, Galveston, TX
Fangjian Guo , Victor Adekanmbi , Ya-Chen Tina Shih , Abbey Berenson , Yong-Fang Kuo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Prevention
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10596)
DOI
10.1200/JCO.2023.41.16_suppl.10596
Abstract #
10596
Poster Bd #
229
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Cost-effectiveness of targeted genomic risk provision to prevent skin cancer: Results of a randomized trial.
First Author: Chi Kin Law
Poster
2022 ASCO Annual Meeting
Cost effectiveness of adjuvant olaparib for BRCA-mutated, early-stage breast cancer.
First Author: Christie Zettler
Poster
2021 ASCO Annual Meeting
Germline testing and somatic tumor testing for BRCA1/2 pathogenic variants in ovarian cancer: What is the optimal sequence of testing?
First Author: Janice S. Kwon
Poster
2020 ASCO Virtual Scientific Program
Breast density notification with adjunctive digital breast tomosynthesis (DBT): A cost-effectiveness analysis.
First Author: Jason Semprini